FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/04/2023
Voltar para busca
Dado oficial do USPTO
HER2DX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
42
Atualização mais recente
12/04/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5
Data de depósito
19/03/2021
Data de registro
29/11/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
29/11/2022
Última transação
29/11/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
ES
Examinador
HAN, DAWN L
Unidade examinadora
L70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
R. S. (pessoa física)
Representantes
Donna A. Tobin Royer Cooper Cohen Braunfeld LLP
Classificação técnica
Classes Nice
Classe 1Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Diagnostic preparations for scientific use; reagents for research purposes; reagents for medical research purposes; diagnostic reagents for scientific use or for research use; reagents for scientific use or for research use in the field of cancer; diagnostic reagents for clinical or medical laboratory use in the field of in vitro in biochemistryclinical chemistry and microbiology
Classe 5
Products for medical diagnosticsmedical diagnostic reagentsmedical diagnostic assays for testing body fluids and tissuespecimen collection kits comprised of swabs for medical purposes and plastic bags for transmitting medical specimensall for use in cancer detection; diagnostic reagents for medical use; diagnostic biomarker reagents for medical purposes; medical reagents for clinical use; medical diagnostic reagents for the analysis of body fluids and tissue; diagnostic reagents for use in diagnostic testing for medical purposes; diagnostic biomarker reagents for cancer diagnosisprognosis and treatment for medical purposes; medical diagnostic kits comprised of medical diagnostic reagents and assays for testing of body fluids and tissuediagnostic reagents for medical useall for cancer diagnosisprognosis and treatment; pharmaceutical products for the treatment of cancer; biological preparations for cancer treatment; biopharmaceutical preparations for cancer treatment; pharmaceutical preparations for the treatment of cancer for oncological use; biological reagentsclinical medical reagents; diagnostic reagent kits consisting primarily of diagnostic reagents for medical usein the field of cancer
Publicações
Histórico de despachos e eventos da marca no USPTO.
42 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
17/03/2023
FIMP
FINAL DISPOSITION PROCESSED
17/03/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
28/02/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
29/11/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
29/11/2022
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
27/11/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/11/2022
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
09/11/2022
GPNX
NOTIFICATION PROCESSED BY IB
03/10/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
13/09/2022
PUBO
PUBLISHED FOR OPPOSITION
13/09/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/09/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
07/09/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
24/08/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/08/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
15/06/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
15/06/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
15/06/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
15/06/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
14/06/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
14/06/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
14/06/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
14/06/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/06/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/06/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/06/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
26/05/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/05/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
26/05/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/05/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/05/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
26/05/2022
RFNT
REFUSAL PROCESSED BY IB
26/12/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/12/2021
RFRR
REFUSAL PROCESSED BY MPU
03/12/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/11/2021
CNRT
NON-FINAL ACTION WRITTEN
02/11/2021
DOCK
ASSIGNED TO EXAMINER
24/10/2021
MAFR
APPLICATION FILING RECEIPT MAILED
11/06/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/06/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/06/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace HER2DX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.